Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - To serve as lead plaintiff, individuals must file a motion with the court by November 7, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Case Allegations - The lawsuit alleges that Savara's defendants made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [4] - It is claimed that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital, contradicting prior representations made to investors [4] - The lawsuit asserts that when the true details became public, investors suffered damages due to the misleading statements [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, of the October 6, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To join the class action, investors can submit a form or contact the law firm for more information [2][5] - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, failing to meet a key statistical significance marker for fibrosis reduction [4] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]

Core Viewpoint - A class action lawsuit has been filed against Charter Communications, Inc. for misleading statements regarding its business operations and the impact of the FCC's Affordable Connectivity Program ending, which allegedly led to investor damages during the specified Class Period [1][5]. Group 1: Lawsuit Details - The class action lawsuit covers purchasers of Charter Communications securities and options between July 26, 2024, and July 24, 2025 [1]. - The lawsuit claims that Charter Communications made false or misleading statements about its ability to manage the impact of the FCC's Affordable Connectivity Program ending, which affected internet customer declines and revenue [5]. - The lawsuit alleges that Charter failed to execute operations effectively to compensate for the adverse effects of the ACP ending, leading to greater risks on business plans and earnings growth than reported [5]. Group 2: Investor Information - Investors who purchased securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must be appointed by October 13, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4]. - The firm emphasizes the importance of selecting qualified counsel with a proven success record in leadership roles [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of KinderCare Learning Companies, Inc. about the upcoming lead plaintiff deadline for a class action lawsuit related to the company's October 2024 IPO [1][3]. Group 1: Class Action Details - Investors who purchased KinderCare common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 14, 2025 [3]. - The lawsuit alleges that the registration statement was false and/or misleading, failing to disclose incidents of child abuse and neglect at KinderCare facilities, and that the company did not meet minimum care standards [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized as a leader in securities class action settlements [4].

Group 1 - The Rosen Law Firm is reminding purchasers of Quantum Corporation securities from November 15, 2024, to August 18, 2025, about the lead plaintiff deadline of November 3, 2025, in a securities class action lawsuit [1] - Investors who purchased Quantum Corporation securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that Quantum Corporation made false and misleading statements regarding its revenue recognition for the fiscal year ending March 31, 2025, which will require a restatement of previously filed financial statements [5] - The misleading statements about Quantum Corporation's business operations and prospects led to investor damages when the true information became public [5] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]

Group 1 - The five Chinese concept stocks with the largest closing declines are Sentage down 29.28%, Kaixin Auto down 25.35%, Zhongyang Financial Group down 21.62%, AieV Auto down 21.20%, and Chuangzhi Global Technology down 18.20% [1][1][1] - Sentage's latest price is 2.850 with a decline of 1.180 and a trading volume of 1.7891 million [1][1] - Kaixin Auto's latest price is 0.799 with a decline of 0.271 and a trading volume of 743,400 [1][1] - Zhongyang Financial Group's latest price is 1.450 with a decline of 0.400 and a trading volume of 2.6265 million [1][1] - AieV Auto's latest price is 0.0788 with a decline of 0.0212 and a trading volume of 3,981.87 [1][1] - Chuangzhi Global Technology's latest price is 0.6945 with a decline of 0.1545 and a trading volume of 1.4339 million [1][1]

Core Viewpoint - Chinese concept stocks experienced significant gains, with Everbright Digital leading the surge with an increase of nearly 90% [1] Group 1: Top Gainers - Everbright Digital (EDHL) saw a price increase of 89.91%, closing at 0.8206 with a trading volume of 150 million [1] - Pitanium (PTNM) rose by 75.06%, reaching a price of 7.930 and a trading volume of approximately 99.664 million [1] - Zhongyang Financial Group (TOP) increased by 49.19%, closing at 1.850 with a trading volume of about 98.6053 million [1] - Chuangzhi Global Technology (CGTL) experienced a gain of 47.37%, closing at 0.8490 with a trading volume of around 69.6471 million [1] - Yipin Weike (EPWK) rose by 38.79%, closing at 0.5363 with a trading volume of approximately 6.1636 million [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Spectrum Pharmaceuticals, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on September 24, 2025, as the lead plaintiff process has been reopened by the Court [1]. Group 1: Class Action Details - Investors who bought Spectrum Pharmaceuticals common stock between May 12, 2022, and September 22, 2022, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed against Spectrum Pharmaceuticals, and interested parties can join by contacting the law firm [3][5]. - The lawsuit alleges that Spectrum made false or misleading statements regarding its PINNACLE Study, which involved the drug poziotinib for lung cancer treatment, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and has recovered hundreds of millions for investors over the years [4]. Group 3: Class Certification Status - No class has been certified yet, meaning investors are not represented by counsel unless they retain one, and they can choose to remain absent from the class [6].

Core Insights - Amgen and Kyowa Kirin announced preliminary top-line results from the ASCEND study, which evaluates rocatinlimab, a T-cell rebalancing therapy targeting the OX40 receptor, for treating moderate to severe atopic dermatitis [1][2] Study Overview - The ASCEND study involves approximately 2,600 patients and assesses the long-term safety and efficacy of rocatinlimab administered at doses of 150 mg and 300 mg every four or eight weeks [2] - The primary endpoint focuses on the long-term safety of rocatinlimab, with a descriptive nature [3] - The study is part of the larger ROCKET Phase 3 clinical program, which includes eight studies aimed at establishing the safety and efficacy profile of rocatinlimab [8][7] Safety and Efficacy Findings - The most common treatment-emergent adverse events in adults included upper respiratory infections, aphthous ulcers, headache, influenza, cough, and rhinitis, with a low discontinuation rate due to adverse events [3][4] - The incidence of gastrointestinal ulceration events with rocatinlimab is less than 1 per 100 patient-years [4] - Secondary endpoints showed that patients who achieved a clinical response in previous trials reported continued therapeutic benefits after one year of treatment [5] Expert Commentary - Amgen's executive vice president highlighted the importance of understanding OX40 inhibition in addressing atopic dermatitis and emphasized the durability of rocatinlimab's response and long-term safety profile [6] - Kyowa Kirin's Chief Medical Officer noted that the results represent a significant milestone in understanding rocatinlimab's ongoing therapeutic benefits, with potential maintenance dosing every eight weeks [6] Future Plans - Amgen and Kyowa Kirin plan to present full results at an upcoming congress or in a peer-reviewed publication [6]

Core Viewpoint - A class action lawsuit has been filed against Dow Inc. for alleged misleading statements regarding its financial condition and ability to manage macroeconomic challenges during the Class Period from January 30, 2025, to July 23, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Dow Inc. overstated its ability to handle macroeconomic and tariff-related challenges, which negatively impacted its business and financial condition [5]. - Specific allegations include the understatement of competitive pressures, softening global sales, and an oversupply of products in Dow's markets [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors in this case [4]. - The firm has a strong track record, having recovered hundreds of millions for investors and being ranked highly in securities class action settlements [4]. - Investors are advised to select qualified legal counsel and can join the class action by contacting the firm [4][6].